| Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes two United States Food and Drug Administration approved products: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-510a, a feline recombinant erythropoietin for the management of anemia in cats; and KIND-511, an anti-Tumor Necrosis Factor treatment for newborn foals. The KIN YTD return is shown above.
The YTD Return on the KIN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KIN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KIN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.